Literature DB >> 6511805

Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular).

M L Hansmann, T Zwingers, A Böske, H Löffler, K Lennert.   

Abstract

Clinical aspects of 145 cases of nodular paragranuloma (nodular subtype of lymphocyte predominance type of Hodgkin's disease) were investigated. There was a marked male predominance, and the age curve showed a peak in the 4th decade. In a majority of cases lymphadenopathy developed within 1 year. General (B) symptoms were observed in only 15 patients. The most frequent sites of primary involvement were cervical, axillary, and inguinal lymph nodes. Other organs were rarely involved. At the time of diagnosis 50% of patients were in stage I, 21% in stage II, 22% in stage III, and 7% in stage IV. The prognosis was usually favorable or very favorable and depended on the stage of disease at diagnosis and on the age of the patient. Patients with stage I or III disease without splenic involvement had about the same probability of survival as the normal population. Stage III patients with splenic involvement had a lower probability of survival. The prognosis for stage II was also less favorable. Patients in stage IV had the lowest probability of survival. Closer analysis of the ten stage IV cases revealed two groups with different outcomes. Four cases showed progressive disease that did not respond to treatment and led to death within 12 months. The second, more favorable form (6 patients) responded well to chemotherapy. Nine patients in stage I who were not treated after lymph node biopsy were free of disease even after periods of up to 14 years. A total of 52 patients had one or more relapses. The recurrent tumors developed locally in a majority of cases. There was transformation of nodular paragranuloma into another subtype of Hodgkin's disease in only four cases. Five cases showed transformation into large-cell tumors that resembled immunoblastic lymphoma and require further immunological study.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6511805     DOI: 10.1007/bf00390466

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  14 in total

1.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

2.  Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases.

Authors:  E B HICKS; H RAPPAPORT; W J WINTER
Journal:  Cancer       Date:  1956 Jul-Aug       Impact factor: 6.860

3.  [Histological classification and occurrence of Hodgkin's disease].

Authors:  K Lennert; N Mohri
Journal:  Internist (Berl)       Date:  1974-02       Impact factor: 0.743

4.  Evidence for an orderly progression in the spread of Hodgkin's disease.

Authors:  S A Rosenberg; H S Kaplan
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

5.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

6.  The "benign" form of Hodgkin's disease (Hodgkin's paragranuloma).

Authors:  C J WRIGHT
Journal:  J Pathol Bacteriol       Date:  1960-07

7.  Nodular paragranuloma and progressively transformed germinal centers. Ultrastructural and immunohistologic findings.

Authors:  S Poppema; E Kaiserling; K Lennert
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1979

8.  Hodgkin's disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centres--a cytohistological study.

Authors:  S Poppema; E Kaiserling; K Lennert
Journal:  Histopathology       Date:  1979-07       Impact factor: 5.087

9.  Epidemiology of nodular paragranuloma (Hodgkin's disease with lymphocytic predominance, nodular).

Authors:  S Poppema; E Kaiserling; K Lennert
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

10.  Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.

Authors:  H Stein; J Gerdes; U Schwab; H Lemke; D Y Mason; A Ziegler; W Schienle; V Diehl
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

View more
  14 in total

1.  Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells.

Authors:  A Braeuninger; R Küppers; J G Strickler; H H Wacker; K Rajewsky; M L Hansmann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Classical Hodgkin's disease. Clinical impact of the immunophenotype.

Authors:  R von Wasielewski; M Mengel; R Fischer; M L Hansmann; K Hübner; J Franklin; H Tesch; U Paulus; M Werner; V Diehl; A Georgii
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group.

Authors:  R von Wasielewski; M Werner; R Fischer; M L Hansmann; K Hübner; D Hasenclever; J Franklin; M Sextro; V Diehl; A Georgii
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

4.  Paragranuloma is a variant of Hodgkin's disease with predominance of B-cells.

Authors:  M L Hansmann; H H Wacker; H J Radzun
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

5.  Correlation of content of B cells and Leu7-positive cells with subtype and stage in lymphocyte predominance type Hodgkin's disease.

Authors:  M L Hansmann; C Fellbaum; P K Hui; T Zwingers
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Hodgkin's disease, lymphocyte predominance type, nodular--further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

Review 7.  Lymphocyte predominant Hodgkin's disease.

Authors:  Bradley C Ekstrand; Sandra J Horning
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

8.  Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

9.  Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Jean François Grellier; Laetitia Vercellino; Thierry Leblanc; Pascal Merlet; Catherine Thieblemont; Pierre Weinmann; Marie-Elisabeth Toubert; Nathalie Berenger; Josette Brière; Pauline Brice
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-26       Impact factor: 9.236

10.  Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.